Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: A decision-tree model

Table 2 Direct medical and productivity costs included into the fesoterodine economic model

Resource costs	Costs	Source
Cost per incontinence pad	0.58 €	[43]
Cost of general practitioner visit	26.78 €	[44]
Cost of specialist visit	58.60 €	[44]
Cost of laboratory tests (urinalysis)	2.56 €	[44]
Constipation cost/day^a	0.16 €	[44]
Fesoterodine 4 mg (cost/day, with taxes)	1.70 €	[43]
Fesoterodine 8 mg (cost/day, with taxes)	2.72 €	[43]
Tolterodine ER (cost/day, with taxes)	1.70 €	[43]
Solifenacin 5 mg (cost/day, with taxes)	1.67 €	[43]
Solifenacin 10 mg (cost/day, with taxes)	2.67 €	[43]
Fracture	5,742.8 €	[45]
Skin Infection episode	53.1 €	[44]
Urinary Tract Infection episode	53.1 €	[44]
Depression (€/patient/year)	2,699 €	[46]
Nursing Home	14,831.4	[44]
Average hourly wage	13.51 €	[47]
Average number of hours worked per week	40	[47]
% Employed in population	59.83%	[47]
Decrease in hours worked due to incontinence ^b	21.1%	[33]
Reduced daytime productivity due to nocturia ^c	9.2%	[34]

^aThe mean cost/day per patient of managing constipation includes a daily dose of oral laxative. ^bWomen without incontinence report working 38 hours/week vs. 30 hours for women with incontinence. ^c 13.8% work impairment for patients with nocturia vs. 4.61% impairment for controls.

ISSN: 1471-2490